Nitric by Aziz U. Momin et al.
Clinical research
Coronary heart disease
Leptin is an endothelial-independent vasodilator in
humans with coronary artery disease: evidence for
tissue speciﬁcity of leptin resistance
Aziz U. Momin
1, Narbeh Melikian
1, Ajay M. Shah
1, David J. Grieve
1, Stephen B. Wheatcroft
1,
Lindsay John
2, Ahmed El Gamel
2, Jatin B. Desai
2, Toby Nelson
1, Catherine Driver
3,
Roy A. Sherwood
3, and Mark T. Kearney
1*
1Cardiovascular Division, King’s College School of Medicine at Guy’s, King’s College, and St Thomas’ Hospitals, King’s College
London, Bessemer Road, London SE5 9PJ, UK;
2Department of Cardiothoracic Surgery, King’s College Hospital, London, UK;
and
3Department of Clinical Biochemistry, King’s College Hospital, London, UK
Received 21 August 2005; revised 11 January 2006; accepted 23 February 2006; online publish-ahead-of-print 16 March 2006
See page 2263 for the editorial comment on this article (doi:10.1093/eurheartj/ehl246)
Aims We sought to deﬁne the mechanisms and correlates of leptin’s vascular actions in humans with
coronary artery disease.
Methods and results In 131 patients (age 65.7+0.7 years mean+SEM), ex vivo vascular reactivity to
leptin (10
213–10
27 M) was assessed in saphenous vein (SV) rings. Leptin led to SV relaxation (maximal
relaxation 24.5 +1.6%). In separate experiments, relaxation to leptin was unaffected by L-NMMA
(17.4 +3.4 vs.17.8+3.3%, P ¼ 0.9) or endothelial denudation (17.4+4.4 vs. 22.5 +3.0%, P ¼ 0.4).
We explored the possibility that leptin’s vascular effects are mediated via smooth muscle hyperpolariz-
ation. In the presence of KCl (30 mmol/L) to inhibit hyperpolarization, the vasodilator effect of leptin
was completely blocked (0.08+4.1%, P , 0.001 vs. control). Similar results were demonstrated in
internal mammary artery rings. The only independent correlate of leptin-mediated vasodilatation
was plasma TNF-alpha (r ¼ 0.25, P , 0.05). Neither body mass index nor waist circumference correlated
with leptin-mediated vasorelaxation. This lack of a correlation with markers of total body fat/fat
distribution suggests that leptin resistance may not extend to the vasculature.
Conclusion Leptin is a vasoactive peptide in human SV and internal mammary artery. Its action is not
nitric oxide or endothelial-dependent. Markers of body fat did not correlate with leptin-mediated
vasodilatation, raising the intriguing possibility of selective resistance to leptin’s actions.
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Introduction
Leptin, the product of the ob gene
1 secreted by adipocytes,
is a multi-functional peptide hormone, the circulating con-
centration of which is proportional to fat mass.
2,3 Leptin
has a major inﬂuence on body weight and metabolism
3,4
and is signiﬁcantly increased in obesity leading to the
concept of leptin resistance.
5,6 Although the hypothalamus
is considered to be the main target for leptin,
7 it is becom-
ing clear that leptin has actions on other tissues. A potential
role for leptin in vascular physiology/pathophysiology
is supported by studies demonstrating that leptin leads
to sympathoactivation,
8 superoxide production,
9 vascular
calciﬁcation,
10 and angiogenesis.
11
A number of studies have demonstrated that leptin is a
vasodilator. The mechanisms underlying this effect are
unclear and results of studies in different species contradic-
tory. In rats, it has been shown that leptin leads to
vasorelaxation, an effect, which may occur by activation
of PI3K/Akt to stimulate endothelial nitric oxide (NO)
synthase.
12–14 Other studies have suggested that leptin
leads to vasorelaxation by smooth muscle hyperpolariz-
ation,
13 whereas a small study in humans did not support a
role for NO in leptin’s vascular effects.
15
We sought to explore the effect of leptin on vascular tone
in human saphenous vein (SV) and internal mammary artery
ex vivo. The present series of studies demonstrate that: (i)
leptin is an endothelial and NO-independent vasodilator in
humans with coronary artery disease; (ii) the vasodilator
action of leptin is at least in part due to smooth muscle
hyperpolarization; and (iii) obesity does not lead to
resistance to the vascular effects of leptin in patients with
coronary artery disease.
Methods
A total of 187 unselected patients referred for ﬁrst time elective
coronary artery bypass surgery (CABG) at King’s College Hospital
(London, UK) between January 2003 and December 2003 were
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 approached to take part in the study. One patient refused to take
part in the study. Of the remaining 186 patients, 131 (91% male)
had vascular function assessed ex vivo (Table 1), and these 131
patients make up the sample described in the present report.
Patients were excluded if they had symptomatic heart failure or an
acute coronary syndrome within the previous 6 months. Patients
were recruited from a pre-admission clinic 1 month prior to
surgery when smoking status (current or within last 6 months) was
ascertained and anthropometric measurements taken. All patients
were taking HMG-CoA reductase inhibitors and anti-platelet
agents, 38% were taking angiotensin converting enzyme inhibitors,
and 69% beta-adrenoceptor blockers. In total, 70% were current/
recent smokers. Drugs were omitted for 24 h prior to surgery. On
the morning of surgery, blood was obtained for measurement of
lipids, C-reactive protein, TNF-alpha (TNF-a), leptin, interleukin-6
(IL-6), and fasting blood glucose. Segments of SV were obtained
from 131 patients (11 female). The study protocol and collection
of tissue specimens were approved by the local research Ethics
Committee and all subjects provided written informed consent.
Vascular ring studies in humans
Vascular responses to human recombinant leptin 10
213–10
27 M
(Calbiochem, UK) were performed in SV and internal mammary
artery rings ex vivo, using techniques as previously described.
16 In
more detail, SV or internal mammary artery was harvested
without distension and minimal tissue handling and transferred in
chilled pre-oxygenated buffer to the physiology laboratory. Veins
and arteries were carefully cleared of adherent tissue and cut
into 4 mm rings. SV and internal mammary artery rings were
suspended between a ﬁxed support and a force transducer in an
organ bath containing 10 mL Krebs Henseleit solution (composition
mmol/L: NaCl 119, KCl 4.7, KH2PO4 1.18, NaHCO3 25, MgSO4 1.19,
CaCl2 2.5, and glucose 11.0) at 378C, bubbled with 95% O2/5% CO2
to maintain a pH of 7.4. After 45 min equilibration at a resting
tension of 3 g, which we have found to be optimal, the maximal
contractile response to 80 mmol/L KCl was assessed. After wash
out and re-equilibration, a cumulative dose-response curve to
phenylephrine was performed (10
29–10
23 M). Rings were then
pre-constricted to 70% of the maximal phenylephrine-induced
tension and relaxation responses to cumulative addition of Ach
(10
29–10
24 M), SNP (10
210–10
24 M), or leptin (10
213–10
27 M) were
determined. Vasodilator responses were expressed as a percentage
of phenylephrine pre-constricted tension.
Exploring the mechanism of leptin-mediated
vasodilatation
In a series of experiments, we assessed potential mechanisms of
leptin-mediated vasodilatation. To do this, we compared the
response with leptin in SV/internal mammary artery in a control
ring and rings treated with the relevant intervention in the same
patient. To assess the role of endothelial derived NO in leptin’s
vascular actions, some studies were performed before and after
exposure to the non-selective nitric oxide synthase inhibitor
L-NMMA 10
24 M (Calbiochem, UK) or after endothelial denudation
(conﬁrmed by response to Ach). To explore the possibility that
leptin’s action is to hyperpolarize vascular smooth muscle, we
added 30 mmol/L KCl prior to exposure to leptin in rings pre-
constricted to 70% maximal tension. Glibenclamide 10 mm/L
(Alexis Corp Nottingham, UK) was used to explore the possibility
that leptin activated ATP-sensitive potassium channels. Some
studies have suggested that H2O2 may be an endothelial derived
hyperpolarizing factor
17 and studies from our own laboratory have
supported a role for H2O2 as a vasodilator in obesity.
18 To explore
the possibility that leptin’s effect was via production of superoxide
and its dismutation product H2O2, we performed leptin relaxation
curves after exposure of rings to catalase at 1250 U/L. Preliminary
studies showed that none of the inhibitors effected SNP-mediated
vasodilatation in SV rings (data not shown).
Plasma assays
Assays for serum total cholesterol, high-density lipoprotein (HDL)
cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides,
and glucose were carried out in the hospital biochemistry labora-
tory. Serum samples for C-reactive protein, TNF-a, and IL-6 were
stored at 2808C until analysis. C-reactive protein was measured
using a high-sensitivity turbidimetric immunoassay (WAKO
Chemicals, Neuss, Germany) on the Cobas Mira Analyser (Roche
Diagnostics, Lewes, UK). The lowest concentration of C-reactive
protein that could be detected was 0.2 mg/L. Within batch variabil-
ity was assessed and a coefﬁcient of variation (CV) of 3.1% at
5.0 mg/L was achieved. TNF-a, IL-6, and leptin were measured
using a commercially available enzyme-linked immunosorbent
assays (R&D Systems, Minneapolis, USA). The CV for TNF-a was
9%, for leptin ,6%, and for IL-6 ,9%.
Statistical methods
Continuous variables are presented as mean +standard error of
mean. Pearson’s correlation coefﬁcients were used to examine
relationships between variables. Non-normally distributed variables
(C-reactive protein, HDL, TNF-a, triglycerides, and leptin) were log
transformed. The independent association between leptin/leptin-
mediated vasodilatation and other variables was analysed by using
stepwise multiple regression analysis with leptin or leptin-mediated
vasodilatation as the dependent variable, and age, gender, body
mass index, waist circumference, mean arterial blood pressure,
fasting glucose, LDL, HDL, triglycerides, TNF-a, IL-6, and C-reactive
protein as covariates. To ensure a minimum of 10 patients per vari-
able entered into the multivariable model .130 were studied.
19 In
studies exploring the mechanisms of leptin’s vascular action, groups
of 10 patients were studied. On the basis of variability of leptin-
mediated vasodilatation, this sample provided 90% power at
P , 0.05 to detect a 50% difference between control and treatment
rings. Paired data were compared using two-sided Student’s t-tests
with application of a Bonferroni correction to adjust for multiple
testing. A value of P , 0.05 was considered signiﬁcant. All analyses
were performed using SPSS, Inc. version 9.0.
Table 1 Characteristics of patients
Characteristic Mean +SEM Range
Age (years) 65.9 +0.8 (40–84)
BMI (kg/m
2) 26.8 +0.3 (16.5–39.1)
Waist (cm) 99.1 +0.9 (73.0–131.0)
WHR 1.0 +0.08 (0.86–1.17)
SBP (mmHg) 138.6 +2.0 (80–200)
DBP (mmHg) 74.4 +1.0 (46.0–104)
Cholesterol (mmol/L) 3.4 +0.08 (1.4–6.8)
LDL (mmol/L) 1.8 +0.06 (0.5–4.4)
HDL (mmol/L) 1.0 +0.02 (0.6–1.9)
Triglycerides (mmol/L) 1.3 +0.07 (0.3–4.0)
Glucose (mmol/L) 6.6 +0.2 (2.7–18.0)
CRP (mg/L) 4.2 +0.7 (0.2–51.0)
TNF-a (mg/L) 3.3 +0.3 (0.5–15.7)
IL-6 (mg/L) 2.8 +0.3 (0.3–25.6)
Leptin (mg/L) 20.1 +2.5 (0.7–194.0)
Data expressed as mean (SEM) or as per cent of population. BMI, body
mass index; WHR, waist-to-hip ratio; SBP, systolic blood pressure; DBP,
diastolic blood pressure.
Leptin’s vascular actions in humans with coronary artery disease 2295
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 Results
Leptin-mediated vasodilatation and its correlates
This ﬁrst part of the present study aimed to assess whether
leptin is a vasodilator in humans and if so does obesity lead
to resistance to leptin’s vascular actions. A large unselected
group of patients undergoing CABG were studied (Table 1).
Leptin-mediated vasodilatation in human SV
and internal mammary artery
Leptin led to signiﬁcant vasodilatation of both SV and
internal mammary artery at both physiological and supra-
physiological concentrations (Figure 1). The extent of vaso-
relaxation to leptin was similar to Ach, whereas all rings
relaxed 100% to SNP.
Determinants of leptin-mediated vasodilatation
in humans
In stepwise multiple regression analysis, body mass index,
waist circumference, and circulating leptin concentration
were not related to leptin-mediated vasodilatation. TNF-a
positively correlated with leptin-mediated vasodilatation
(B ¼ 12.0 + 5.4, Beta ¼ 0.25, 95% CI 1.2–22.8, P , 0.05).
Potential mechanisms underlying leptin-mediated
vasodilatation in humans
In a subgroup of patients, we explored the potential mechan-
isms underlying leptin’s vascular effects. Each patient acted
as their own control with an untreated SV ring exposed to
leptin compared with treated rings. To explore the role of
theendotheliumandendothelialderivednitricoxide,weper-
formed studies in rings denuded of endothelium and in the
presenceofL-NMMA(n ¼ 10inallgroups).Maximalrelaxation
to leptin was 17.5 + 3.4% in endothelial intact rings,
17.8 + 3.3% in the presence of L-NMMA, and 22.5 + 3.0%
after endothelial denudation (P-value difference all .0.6).
To explore the possibility that leptin acts on blood vessels
by hyperpolarizing vascular smooth muscle, we exposed
rings to KCl 30 mmol/L (n ¼ 10). Mean relaxation after KCl
was 0.08 + 4.1%. To explore the possibility that hydrogen
peroxide contributes to leptin-mediated vasodilatation, we
performed relaxation before and after exposure of rings to
catalase (1250 U/L, n ¼ 10). Catalase had no effect on
leptin-mediated relaxation of SV rings (Figure 1B).
To explore the possibility that the vascular effects of leptin
arespeciﬁctoveins,werepeatedtheexperimentsinasubset
of internal mammary artery rings from similar patients, each
patienthavinganuntreatedcontrolinternalmammaryartery
ring(n ¼ 10inallgroups,Figure2).Inarterialrings,leptinled
to vasorelaxation of 30.5 + 8.1%. This response was unaf-
fected by L-NMMA (48.4 + 10.6%) or endothelial denudation
(37.9 + 5.8%) (all P . 0.4 vs. control rings). Hyperpolariz-
ation with KCl blocked this effect, mean relaxation
20.62 +1.8% (P , 0.05 vs. control).
Determinants of circulating leptin in humans
with coronary artery disease
Signiﬁcant correlates of plasma leptin are shown in Table 2.
In stepwise multiple regression analysis, independent
Figure 1 (A) Vasodilator dose-response curves for leptin in human SV (n ¼ 131 patients). (B) Studies exploring mechanisms of leptin-mediated vasodilatation
in human SV (n ¼ 10 for all studies; asterisk denotes P , 0.05 vs. control; den, endothelial denuded; glib, glibenclamide). (C) Vasodilator dose-response
curves for acetylcholine in human SV (n ¼ 131). (D) Vasodilator dose-response curves for sodium nitroprusside in human SV (n ¼ 131).
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 predictors of plasma leptin concentration were body mass
index (B ¼ 0.03 +0.01, Beta ¼ 0.30, 95% CI 0.008–0.047,
P , 0.01), waist circumference (B ¼ 0.014 + 0.004,
Beta ¼ 0.35, 95% CI 0.005–0.022, P , 001), and fasting
plasma glucose (B ¼ 0.58 + 0.17, Beta ¼ 0.21, 95% CI
0.23–0.93, P , 0.01).
Discussion
The novel ﬁnding of the present report is that leptin is an
endothelial-independent vasodilator in humans with coro-
nary artery disease, an effect that does not seem to be
blunted in patients with increased adiposity. This ﬁnding
suggests that leptin resistance may be tissue-speciﬁc in
obesity (i.e. it does not effect the vascular system).
The adipocyte as a vasoregulatory organ
In recent years, the view of adipose tissue as a simple fuel
store has changed. Fat tissue has emerged as a complex
endocrine organ.
20 This concept has evolved further to
include a role for fat tissue in inﬂammatory pathways,
largely as adipocytes have been shown to secrete cytokines
classically considered to be produced by macrophages.
These cytokines include IL-6 and TNF-a, both of which are
signiﬁcantly increased in obese humans.
21 Furthermore,
recent studies have suggested that the adipocyte may
secrete substances that regulate vascular tone.
22–24 Soltis
and Cassis
22 demonstrated that the presence of peri-
adventitial fat blunts vascular responsiveness of rat aortic
rings to norepinephrine. Verlohren et al.
24 studied mesen-
teric rings from Sprague–Dawley rats, and demonstrated
that the contractile response to a number of vasoconstrictors
was attenuated by an adipocyte-derived substance. Similar
to our ﬁndings with leptin, they demonstrated that this
vasorelaxant effect was blunted by high K
þ solutions.
Leptin-mediated vasorelaxation
In a series of experiments, Lembo and coworkers
13,14
demonstrated that leptin has a vasorelaxant action in rat
aortic rings. They also showed that this effect was blun-
ted by endothelial denudation, L-NAME, and a selective
guanylate cyclase inhibitor (consistent with a role for
endothelium-derived NO).
13 In mesenteric rings, however,
the effect of leptin was unaffected by L-NAME, but
blunted by Befeldin, an endothelial-derived hyperpolarizing
factor inhibitor.
Our data in humans show that leptin is a vasodilator both
in veins and arteries. This action is neither endothelium nor
NO-dependent. Leptin is thought to exert its central actions
by membrane hyperpolarization,
25 an effect also demon-
strated in pancreatic beta-cells.
26 Consistent with a similar
effect in vascular smooth muscle cells, we demonstrated
that increasing local K
þ concentration blocks leptin’s vasor-
elaxant effect in both arteries and veins. We explored the
possibility that glibenclamide (a commonly prescribed
agent in obese diabetics) that blocks potassium channels
blocks leptin’s vasodilatory effect. In the presence of gliben-
clamide, leptin’s effect was unchanged. The precise mech-
anism of leptin-mediated smooth muscle hyperpolarization
warrants further study.
Determinants of leptin-mediated vasodilatation:
potential implications for vascular regulation in
inﬂammatory conditions
Recent studies have demonstrated that plasma leptin con-
centration rises in sepsis in humans.
27 Moreover, there are
compelling data that TNF-a can stimulate release of pre-
formed adipocyte stores of leptin.
28 Our data may thus
have potential implications for vascular homeostasis in
human conditions associated with inﬂammation such as
sepsis, obesity, and diabetes. It is well established that
sepsis is characterized by hypotension and peripheral vaso-
dilatation; thus leptin and its interaction with cytokines
may contribute to this. Our ﬁndings suggest that TNF-a
may augment the vasodilator action of leptin on capacitance
veins. Venous tone plays an important role in blood pressure
homeostasis
29,30 and is depressed in sepsis.
31 This poten-
tially important interaction between leptin and TNF-a on
vascular tone warrants further study. It is also important
to note that markers of body fat were not related to leptin-
mediated vasodilatation. Although the presence of leptin
resistance in obesity has been reported, our data set
supports tissue selectivity of resistance to leptin with
preservation of leptin’s vasodilatory effects. This may
reﬂect different mechanisms underlying leptin’s vascular
and metabolic/central effects—studies at the whole body
level in humans may help answer this question.
What are the determinants of circulating leptin
in patients with coronary artery disease?
In view of the fact that leptin seems to have potentially
favourable (at least in terms of obesity-related hyperten-
sion) vascular effects, and that increased total and visceral
Figure 2 Maximal vasodilator response to leptin in internal mammary artery
segments (n ¼ 10 for all patients; den, endothelial denuded; asterisk denotes
P , 0.05 vs. control).
Table 2 Pearsons correlation coefﬁcients for circulating leptin
concentrations in patients with severe coronary artery disease
Variable Pearson’s correlation
coefﬁcient
P-value
BMI (kg/m
2) 0.59 0.0001
Waist circumference (cm) 0.58 0.0001
MABP (mmHg) 0.27 0.002
Triglycerides (mmol/L) 0.19 0.02
C-reactive protein (mg/L) 0.22 0.01
Fasting glucose (mmol/L) 0.26 0.003
MABP, mean arterial blood pressure.
Leptin’s vascular actions in humans with coronary artery disease 2297
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 fat do not blunt this effect, the determinants of circulating
leptin in this sample were explored. Shamsuzzaman et al.
32
recently demonstrated an independent association between
leptin and C-reactive protein in healthy subjects. This study,
however, did not include variables such as blood glucose,
blood pressure, or inﬂammatory cytokines. In a larger
retrospective analysis of the West of Scotland Coronary
Prevention database, Wallace et al.
33 demonstrated in
men with moderate hypercholesterolaemia without docu-
mented coronary artery disease, that leptin correlated
with a number of major coronary risk factors including
cholesterol, blood pressure, and C-reactive protein.
Independent predictors of leptin were not reported in this
study. In the present report exploring the correlates of
leptin in patients with severe coronary disease, we found
a signiﬁcant relationship between leptin and body mass
index, waist circumference, and fasting plasma glucose.
The effect on plasma leptin of changing these variables in
obese or diabetic patients with coronary artery disease
warrants further study.
Study limitations
The present study explored leptin’s effects on vascular func-
tion in humans with coronary artery disease and the mech-
anisms underlying these effects in an ex vivo model. The
advantages of this model are that it allows detailed pharma-
cological studies to be performed in large numbers of
patients. The sample studied, however, are patients with
severe coronary artery disease and extrapolation of these
results to other groups and vascular territories should be
performed with caution. It would therefore be useful to
conﬁrm our ﬁndings in subjects without coronary artery
disease.
Clinical and in vivo relevance of present report
Previous studies exploring the effect of leptin on vascular
function have found discordant results. The present
report, in a large group of individuals, demonstrates for
the ﬁrst time in humans that leptin is an endothelium and
NO-independent vasodilator. The effect is of potential clini-
cal relevance to patients with coronary artery disease or
those at risk of developing coronary artery disease,
whereby leptin may have a favourable effect on vascular
function. In contrast, our ﬁnding of a vasodepressor effect
of leptin, which may be augmented by TNF-a, may be of rel-
evance to sepsis when both leptin and TNF-a are elevated
and may therefore contribute to the hypotension seen in
humans with systemic sepsis. Our ﬁndings provide a starting
point for the study of leptin’s vascular actions in different
vascular pathologies.
The adipocyte is now recognized as being not only an
important storage organ for triglyceride but also an active
endocrine organ.
34 In addition to leptin, adipocytes
produce a number of potentially vasoactive substances
including fatty acids,
35 angiotensin II,
36 and adiponectin.
37
Moreover, leptin has been shown to stimulate sympathetic
neural trafﬁc.
38 Hence, in obesity, these different factors
may unite to inﬂuence the effect of leptin on vascular
tone in vivo.
Studies of vascular function in humans are largely per-
formed in vivo. In this situation, it is difﬁcult to control for
factors such as baseline vessel tone, neural, or humoral
inﬂuences. The ex vivo system used in the present series of
studies removes these inﬂuences. It should be, therefore,
borne in mind that in the intact organism, multiple
interactions may effect leptin’s vascular action. Despite
this limitation, however, previous studies in patients, using
an ex vivo system similar to ours have demonstrated data
consistent and complimentary to in vivo studies.
39
The present series of studies demonstrate that leptin is a
vasodilator in both human SV and internal mammary artery.
Leptin-mediated vasodilatation is not dependent on an
intact endothelium and is likely to be at least in part due
to smooth muscle hyperpolarization. We have demonstrated
that this effect is not blunted in obese humans consistent
with the intriguing concept of tissue speciﬁcity of resistance
to leptin.
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